BVS
Bioventus Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Bioventus Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Last report0 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Bioventus Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of Bioventus Inc.'s 6 closest co-movers, none share that code.
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Bioventus Inc.
10.95
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Essex Woodlands Health Ventures | $122.9M | 24.06% | 0.00% |
| Juniper Investment | $65.5M | 12.82% | 0.00% |
| Nantahala | $56.6M | 11.09% | −1.99% |
| BlackRockindex-like | $32.4M | 6.35% | +9.65% |
| Royce & | $17.3M | 3.39% | +18.94% |
| Manager | Value | % base | |
|---|---|---|---|
| Essex Woodlands Health Ventures | $122.9M | 24.06% | 0.00% |
| Juniper Investment | $65.5M | 12.82% | 0.00% |
| Nantahala | $56.6M | 11.09% | −1.99% |
| BlackRockindex-like | $32.4M | 6.35% | +9.65% |
| Royce & | $17.3M | 3.39% | +18.94% |
—
—
Expected move
Inputsspot 10.95exp Apr 16ATM strike 10ATM straddle 3.55IV 62%